Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Allows Pharma To Temporarily Prioritize Reporting For COVID-19 Adverse Events

Prioritization Allowed Until The Pandemic Is Resolved

Executive Summary

Drug companies unable to continue with standard reporting of suspected adverse reactions to the EU pharmacovigilance database can temporarily prioritize their reporting activities to focus on COVID-19 related safety events.

You may also be interested in...



COVID-19 Pandemic Pushes EU To Extend GMP/GDP Certificate Validity

As the COVID-19 pandemic continues to pose difficulties in conducting on-site inspections to check compliance with good manufacturing and distribution requirements, regulators in the EU have extended the validity of existing certificates and time-limited authorizations till the end of next year.

World’s Pharmaceutical Inspectorates Prepare For Post-Pandemic Remote Site Assessments

US, EU, global authorities share experiences, insights, advice for industry on remote alternatives even after inspectors can resume travels.

How EFPIA Set The Bar On Drug Safety Reporting During COVID-19

Early disruptions caused by the coronavirus pandemic prompted the European pharmaceutical industry body, EFPIA, to establish a principles-based framework to help ensure consistency in managing compliance with pharmacovigilance responsibilities. 

Related Content

Topics

UsernamePublicRestriction

Register

PS142060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel